Skip to main content
Journal cover image

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Publication ,  Journal Article
Aulin, J; Hijazi, Z; Siegbahn, A; Andersson, U; Alexander, JH; Connolly, SJ; Ezekowitz, MD; Gersh, BJ; Granger, CB; Horowitz, J; Hylek, EM ...
Published in: J Thromb Haemost
September 2020

BACKGROUND: The inflammatory biomarker interleukin-6 (IL-6) is associated with mortality in atrial fibrillation (AF). OBJECTIVE: To investigate if repeated IL-6 measurements improve the prognostication for stroke or systemic embolism, major bleeding, and mortality in anticoagulated patients with AF. METHODS: IL-6 levels by ELISA were measured at study entry and at 2 months in 4830 patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial with 1.8 years median follow-up. In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, IL-6 was measured at study entry, 3, 6, and 12 months in 2559 patients with 2.0 years median follow-up. Associations between a second IL-6 measurement and outcomes, adjusted for baseline IL-6, clinical variables, and other cardiovascular biomarkers, were analyzed by Cox regression. RESULTS: Median IL-6 levels were 2.0 ng/L (interquartile range [IQR] 1.30-3.20) and 2.10 ng/L (IQR 1.40-3.40) at the two time-points in ARISTOTLE, and, in RE-LY, 2.5 ng/L (IQR 1.6-4.3), 2.5 ng/L (IQR 1.6-4.2), 2.4 ng/L (IQR 1.6, 3.9), and 2.4 ng/L (IQR 1.5, 3.9), respectively. IL-6 was associated with mortality; hazard ratios per 50% higher IL-6 at 2 or 3 months, respectively, were 1.32 (95% confidence interval, 1.23-1.41; P < .0001) in ARISTOTLE, and 1.11 (1.01-1.22, P = .0290) in RE-LY; with improved C index from 0.74 to 0.76 in ARISTOTLE, but not in the smaller RE-LY cohort. There were no consistent associations with second IL-6 and stroke or systemic embolism, or major bleeding. CONCLUSIONS: Persistent systemic inflammatory activity, assessed by repeated IL-6 measurements, is associated with mortality independent of established clinical risk factors and other strong cardiovascular biomarkers in anticoagulated patients with AF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thromb Haemost

DOI

EISSN

1538-7836

Publication Date

September 2020

Volume

18

Issue

9

Start / End Page

2287 / 2295

Location

England

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Stroke
  • Risk Assessment
  • Pyridones
  • Interleukin-6
  • Humans
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aulin, J., Hijazi, Z., Siegbahn, A., Andersson, U., Alexander, J. H., Connolly, S. J., … Oldgren, J. (2020). Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost, 18(9), 2287–2295. https://doi.org/10.1111/jth.14947
Aulin, Julia, Ziad Hijazi, Agneta Siegbahn, Ulrika Andersson, John H. Alexander, Stuart J. Connolly, Michael D. Ezekowitz, et al. “Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.J Thromb Haemost 18, no. 9 (September 2020): 2287–95. https://doi.org/10.1111/jth.14947.
Aulin J, Hijazi Z, Siegbahn A, Andersson U, Alexander JH, Connolly SJ, et al. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost. 2020 Sep;18(9):2287–95.
Aulin, Julia, et al. “Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.J Thromb Haemost, vol. 18, no. 9, Sept. 2020, pp. 2287–95. Pubmed, doi:10.1111/jth.14947.
Aulin J, Hijazi Z, Siegbahn A, Andersson U, Alexander JH, Connolly SJ, Ezekowitz MD, Gersh BJ, Granger CB, Horowitz J, Hylek EM, Lopes RD, Yusuf S, Wallentin L, Oldgren J. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost. 2020 Sep;18(9):2287–2295.
Journal cover image

Published In

J Thromb Haemost

DOI

EISSN

1538-7836

Publication Date

September 2020

Volume

18

Issue

9

Start / End Page

2287 / 2295

Location

England

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Stroke
  • Risk Assessment
  • Pyridones
  • Interleukin-6
  • Humans
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants